Australian National Diabetes Information Audit & Benchmarking (ANDIAB) 2011 Final Report

2.7.6 Other Data Analyses

Data on age, BMI, diabetes duration, gender, initial visit, indigenous status, currently pregnant individuals, smoking status and type of diabetes by treatment

Page last updated: December 2011

Appendix 6 provides data [by diabetes type] for Age, BMI & Diabetes Duration, which have not otherwise been referred to [apart from the BMI component of the Age, BMI & Diabetes Duration graphs {Table 12 page 19 above & pages 103-106 Appendix 5}]. Also presented are the data for Gender, Initial Visit, Indigenous Status and Currently Pregnant, as well as Smoking status and finally, Type of Diabetes by Treatment.

These data [most of which are very similar to those found in 2004, 2006 and 2009] show:

A slight preponderance of males with Type 1 [51.0%] & males with Type 2 [55.6%] overall.

Sex
Type 1
Type 2
Male %
51.0%
55.6%
Mean Age 39.3 17 years Type 1, 63.5 12.4 years Type 2, 32.8 8.7 years GDM overall.
Age
Type 1
Type 2
GDM
Mean + SD
39.3 17
63.5 12.4
32.8 8.7
Mean BMI 26.6 6.2 kg/m2 Type 1 and 32.8 7.4 kg/m2 Type 2 overall.
BMI
Type 1
Type 2
GDM
Mean + SD
26.6 6.2
32.8 7.4
31.9 7
Mean Diabetes Duration 17.8 13.4 years Type 1 and 13.1 9.1 years Type 2 overall.
Duration
Type 1
Type 2
GDM
Mean + SD
17.8 13.4
13.1 9.1
0.4 1.1
Treatments for Type 2 data are, in general, similar to 2004 2006 and 2009 [data shown for comparison] with (versus 2009) less on Diet alone, less on Tablets and more on Insulin or Insulin plus Tablets [NB Percentages calculated on those where a Therapy type was stated]:
Treatment for Type 2
2004
2006
2009
2011
Diet Only
8.1%
5.7%
6.8%
5.0%
Tablets
47.2%
49.0%
40.1%
37.4%
Insulin
15.8%
13.7%
18.2%
18.5%
Insulin &Tabs
27.8%
31.4%
34.9%
39.1%
‘Nil’
1.0%
0.2%
0.0%
0.0%
A breakdown of oral therapies reported follows – Patients are often on more than one Tablet [but only 5.9% reported to be on triple therapy in 2011] - see below.
Tablet Treatment for Type 2
%
Metformin
90.6%
Sulphonylurea
43.4%
Glitazone
5.8%
GLP1 Agonist
3.0%
DPP4 Inhibitor
7.6%
Acarbose
1.5%
Missing
4.4%
Number of Tablets
1 Tablet
2 Tablets
3 Tablets
4 Tablets
5 Tablets
Diabetes Tablets
2011
56.6%
37.2%
5.9%
0.3%
0.0%
Diabetes Tablets
2009
54.0%
39.3%
6.5%
0.2%
0.0%
Those on 4 Tablets (n=8 from 5 different Sites) were recorded as being on Triple Therapy [Metformin, Sulphonylurea and a Glitazone] – plus Acarbose (3), [Metformin, Sulphonylurea and a DDP4Inhibitor] – plus Acarbose (2), [Metformin, Sulphonylurea and a GLP1Agonist] – plus Acarbose (1), [Metformin, Sulphonylurea and a Glitazone] – plus a DDP4 Inhibitor (1), [Metformin, Sulphonylurea and a Glitazone] – plus a GLP1Agonist (1).

Also shown are data for the number of agents used for Blood Pressure and Lipid Therapy in 2011, with 2009 and 2006 data for comparison, the findings being similar except for more on 2 as opposed to only 1 Anti-Lipid Tablet in 2011.
Number of Tablets
1 Tablet
2 Tablets
3 Tablets
4 Tablets
5 Tablets
Anti - Hypertensive
2011
47.2%
31.6%
14.8%
5.0%
1.1%
2009
44.5%
33.7%
15.6%
4.7%
1.4%
2006
46.5%
33.5%
14.3%
5.1%
0.6%
Number of Tablets
1 Tablet
2 Tablets
3 Tablets
4 Tablets
5 Tablets
Anti - Lipid
2011
83.4%
15.3%
1.3%
0.0%
0.0%
2009
89.5%
9.5%
0.8%
0.1%
0.0%
2006
92.5%
6.6%
0.6%
0.2%
0.1%
[Also see Tables on pp 189-194 Appendix 5 and pp 219-220 Appendix 6].

More data analyses:

Aspirin / Clopidogrel

Additionally, we have again undertaken some additional assessments (based on recommendations received in feedback from an Endocrinologist following ANDIAB 2002).

Tables on Pages 141-154 of Appendix 5 show the breakdown of the number of complications at any time ** [Adult Forms only] by Diabetes Type – thence further assessed by Current Smoker = Yes [n=457] versus Current Smoker = No [n=2920] for macrovascular complications only. Note: this includes data from 7 Electronic Sites who use this ‘old’ Field format, plus a conversion of the new Smoking Field data from other sites, to this format.

[Also see Tables on Pages 217-218 Appendix 6 re Smoking Status].

**Possible complications are: Cerebral Stroke, CABG / Angioplasty, Myocardial Infarction, End Stage Renal Disease, Lower Limb Amputation and Blindness. Each of these complications can be new or previous. Occurrence of a complication, both in the past 12 months and previously, is counted once only. Peripheral Neuropathy and Peripheral Vascular Disease are counted as separate current complications.

Complications

[a] Overall Complications
[b] Vascular Complications & Smoking Status
[c] Cardiac Disease and Lipid Therapy
[d] Vascular Disease and Anti-Hypertensive Therapy

Document download

This publication is available as a downloadable document.

Australian National Diabetes Information Audit & Benchmarking (ANDIAB) 2011 Final Report(PDF 559 KB)